Cannabinol, better known as CBN, has rapidly become one of the medicinal cannabis industry’s most popular ingredients for nighttime gummies, tinctures and capsules. Frequently marketed as the “sleepy cannabinoid,” CBN is often positioned as a gentler alternative to THC for consumers who want help sleeping without a strong marijuana high. New research from scientists at the University of Connecticut, RTI International and Rice University, however, suggests that repeated exposure may produce some of the same biological adaptations associated with THC.
The study, published in 2026 in the journal Drug and Alcohol Dependence, found that mice repeatedly given CBN developed tolerance to several cannabinoid effects and showed signs of physical dependence when cannabinoid signaling was abruptly blocked. Researchers also found that animals trained to recognize the internal effects of THC responded to CBN as though they had received THC. The findings do not establish that people who take commercial CBN sleep products will become addicted, but they challenge the assumption that minor cannabinoids marketed as natural supplements are automatically free of dependence-related risks.
Researchers Tested What Happens After Repeated CBN Exposure
The study was led by S. Olivia Vanegas and colleagues and was designed specifically to address an important gap in cannabinoid research. Scientists know considerably more about the effects of repeated THC exposure than they do about CBN. THC can produce tolerance, meaning progressively larger exposure may be required to produce the same effects, and repeated use can lead to physical dependence in which withdrawal symptoms emerge after cannabinoid receptor activity is suddenly reduced. Whether CBN could produce similar adaptations had received little direct study.
Adult mice were given CBN twice daily for five days. Researchers used a well-established cannabinoid testing system known as the tetrad battery to measure several characteristic effects of cannabinoids, including changes in pain sensitivity, body temperature, movement and catalepsy. On the sixth day, animals were given rimonabant, a compound that blocks the CB1 cannabinoid receptor and can precipitate withdrawal in animals that have become physically dependent on cannabinoid agonists. Separate experiments examined cross-tolerance and whether CBN produced internal drug effects similar enough to THC that mice could distinguish them from an inactive vehicle.
Repeated CBN Produced Clear Signs of Tolerance
One of the clearest findings was that several effects of CBN became weaker after repeated administration. Mice developed tolerance to CBN-induced catalepsy, antinociception and hypothermia. In other words, the same cannabinoid exposure produced smaller changes in movement, pain response and body temperature after the animals had been repeatedly exposed. Tolerance is an important pharmacological sign that the nervous system is adapting to a drug.
Researchers also tested the animals with WIN 55,212-2, a synthetic compound that activates CB1 and CB2 cannabinoid receptors. Mice previously exposed to repeated CBN showed reduced responses to this compound as well, demonstrating cross-tolerance. That result is particularly interesting because cross-tolerance suggests that the adaptations caused by CBN overlap with biological mechanisms used by other cannabinoid receptor agonists rather than representing an isolated effect unique to CBN.
Withdrawal Testing Pointed to Physical Dependence
The dependence portion of the experiment produced an even more consequential result. After repeated CBN treatment, researchers administered rimonabant, which blocks the CB1 receptor. The animals subsequently displayed increased head twitches, paw tremors and struggling behavior. These are established signs used in laboratory models of cannabinoid withdrawal.
The researchers concluded that repeated CBN administration had produced physical dependence in the mice. That does not mean the animals were “addicted” in the everyday sense of compulsively seeking CBN. Physical dependence describes physiological adaptation to repeated drug exposure, while addiction involves a broader behavioral pattern that can include craving, loss of control and continued use despite harm. A person taking certain prescription medicines can become physically dependent without developing addiction. The distinction is particularly important when interpreting animal studies involving cannabinoids.
CBN Produced THC-Like Internal Drug Effects
Another experiment produced one of the study’s most striking findings. Researchers trained a separate group of mice to recognize the internal effects produced by THC and distinguish them from an inactive injection. Drug-discrimination experiments are frequently used in behavioral pharmacology to determine whether one substance produces subjective-like internal cues resembling another drug.
CBN fully substituted for THC in the test. From the perspective of the trained animals’ behavioral response, CBN generated an internal cue sufficiently similar to THC that the mice treated it as the same kind of stimulus. The finding does not prove that CBN produces an identical marijuana high in humans, and decades of limited human research have generally suggested that isolated CBN is substantially less intoxicating than THC. It does demonstrate, however, that CBN can engage neural systems strongly enough to produce THC-like effects under experimental conditions.
CBN and THC May Interact in Unexpected Ways
The new study also examined what happened when CBN and THC were given together. Surprisingly, CBN reduced the strength of THC’s discriminative stimulus rather than simply adding to it. The researchers therefore found evidence of both overlap and interaction: CBN could mimic THC when given by itself, yet could also weaken some of THC’s internal effects when the two cannabinoids were combined.
Rimonabant added another layer of complexity. Blocking CB1 receptors strongly reduced the discriminative effects of THC, as expected, but the particular dose used in the study was less effective at blocking CBN’s THC-like cue. That suggests CBN’s pharmacology may not simply represent a weaker copy of THC. CBN appears capable of acting through CB1-dependent mechanisms while also influencing additional biological targets, a pattern supported by other recent studies examining its anti-inflammatory and analgesic effects.
Earlier Research Already Found THC-Like Effects at Higher CBN Doses
The dependence findings build on research published earlier in 2026 by Vanegas and colleagues in the Journal of Cannabis Research. That study compared several lesser-known cannabinoids and found CBN produced the most complete classic cannabinoid response among the minor compounds tested. At sufficiently high doses, CBN produced antinociception, hypothermia, reduced movement and catalepsy in mice. Blocking CB1 receptors with rimonabant eliminated or reduced several of those effects, demonstrating that cannabinoid receptor signaling was at least partly responsible.
That earlier research also found potential therapeutic activity. CBN reduced inflammatory swelling and inflammatory cytokines in a mouse model and reduced signs of neuropathic pain. However, some of the doses associated with analgesic effects also produced catalepsy and hypothermia. Together with the new dependence study, the results illustrate a recurring issue in cannabinoid drug development: a compound may possess useful biological activity while also producing unwanted effects as exposure increases.
Why CBN Became Popular as a Sleep Aid
CBN is not a newly discovered cannabinoid. It was identified more than a century ago and is produced naturally as THC oxidizes over time. Older cannabis tends to accumulate more CBN as THC is exposed to oxygen, heat and light. For decades, anecdotal reports associated aged cannabis with sleepiness, eventually helping create the theory that CBN itself was a powerful sedative.
Commercial interest expanded much faster than clinical research. Today, purified CBN can be found in products marketed specifically for sleep, often combined with CBD, THC, melatonin or botanical ingredients. Earlier reviews of the scientific literature noted that evidence supporting CBN as a sleep aid was surprisingly thin despite widespread marketing. A 2021 review titled Cannabinol and Sleep: Separating Fact from Fiction found insufficient clinical evidence at that time to support many of the sleep claims surrounding CBN and called for controlled trials using validated sleep measurements.
Animal Sleep Research Has Found Real Effects
Evidence supporting a potential sleep effect has strengthened since that review. A University of Sydney-led study published in Neuropsychopharmacology examined CBN using objective sleep measurements in rats. Researchers found that CBN increased total sleep time, increased both non-rapid eye movement and rapid eye movement sleep and reduced wakefulness. Its effect on NREM sleep was comparable in magnitude to the prescription sleep medicine zolpidem in the experiment, although CBN acted differently and had a delayed sleep-promoting effect.
That study also produced a finding that may help explain CBN’s pharmacology. Researchers discovered that 11-hydroxy-CBN, a major metabolite produced after the body processes CBN, reached substantial concentrations in the brain. In laboratory receptor experiments, 11-hydroxy-CBN acted at CB1 receptors with potency and efficacy comparable to THC, despite CBN itself showing substantially weaker activity. Repeated CBN administration also showed evidence of tolerance to some of its sleep effects, providing an earlier warning that regular exposure could produce adaptation.
Human Sleep Trials Have Produced Promising but Mixed Results
Human studies are beginning to fill some of the gaps. A randomized, double-blind, placebo-controlled study published in Experimental and Clinical Psychopharmacology evaluated 293 adults who described their sleep quality as poor or very poor. Participants received placebo, 20 milligrams of CBN alone or CBN combined with different amounts of CBD for seven nights. The CBN-only group experienced fewer nighttime awakenings and lower overall sleep disturbance compared with placebo, although the study’s primary overall sleep-quality outcome did not reach conventional statistical significance. Adding CBD did not improve the sleep effects of CBN.
A more recent randomized crossover trial published in 2026 studied 20 adults with clinically diagnosed insomnia using objective overnight polysomnography. Participants received either 30 milligrams of CBN, 300 milligrams or placebo on separate nights. CBN did not significantly improve the study’s primary measure of wake time after sleep onset. The 300-milligram dose did, however, shorten sleep-onset latency, improve subjective sleep quality, increase stage-2 NREM sleep and reduce EEG-measured arousals. Researchers concluded that larger and longer trials were needed before determining CBN’s role as an insomnia treatment.
Mouse Dependence Does Not Prove Human CBN Addiction
The biggest limitation of the new dependence study is straightforward: it was conducted in mice. Animal models are extremely useful for identifying pharmacological mechanisms, but doses, drug administration routes, metabolism and behavior do not translate directly into human use. A mouse receiving experimental CBN injections twice each day cannot simply be compared with a person taking a low-dose gummy before bed.
Human studies have also historically found weaker psychoactive effects from CBN than the new mouse experiments might imply. Research dating back to the 1970s and 1980s administered isolated CBN to volunteers at a wide range of doses and generally failed to find the characteristic intoxication produced by THC. A modern review of those experiments concluded that the majority of available human evidence did not show meaningful cannabis-like intoxication from CBN alone. The newest animal results therefore raise a question rather than settle it: could repeated exposure produce dependence-related adaptations in humans even when users do not experience a pronounced high?
Commercial CBN Products Are Ahead of the Science
The issue is particularly relevant because consumers can already purchase CBN products in many places without the type of clinical testing required for prescription sleep medications. Product labels frequently use terms associated with relaxation, nighttime recovery or sleep even though researchers are still determining appropriate doses, long-term safety and dependence potential.
That creates a very different environment from traditional drug development, where extensive safety testing generally occurs before millions of consumers gain access. Minor cannabinoids such as CBN, CBG, CBC and delta-8 THC entered large consumer markets while basic pharmacology was still being characterized. Similar research on delta-8 THC previously demonstrated tolerance and physical dependence in mice, showing how compounds marketed as milder alternatives to conventional THC can still engage the same biological pathways involved in cannabinoid withdrawal.
The New Study Changes the Risk Conversation Around CBN
The latest research does not establish that CBN should be avoided or that every nightly user will develop dependence. CBN continues to show potential therapeutic effects involving sleep, pain and inflammation, and controlled human studies have produced some encouraging findings. What the study does challenge is the idea that CBN can be treated as biologically insignificant simply because it is a minor cannabinoid or is marketed as an herbal sleep supplement.
Repeated CBN exposure produced tolerance, cross-tolerance, physical dependence and THC-like drug-discrimination effects in mice—four findings that warrant much closer investigation in people. Researchers now need longer human trials that examine whether nightly CBN use becomes less effective over time, whether stopping after repeated use produces insomnia or other withdrawal symptoms, and how commercial doses compare with exposure levels associated with dependence in laboratory animals. Until those questions are answered, CBN’s rapidly growing reputation as a gentle cannabis sleep aid is moving faster than the science needed to define its long-term risks.
